Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pelvic inflammatory disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Pelvic inflammatory disease. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2009-014619-11 Sponsor Protocol Number: Kotoe_01 Start Date*: 2009-10-09
    Sponsor Name:Pirkanmaan sairaanhoitopiiri
    Full Title: The effect of dexmedetomidine on reactivity of a propofol-anaesthetized patient
    Medical condition: Surgical patients scheduled for elective surgery under general anaesthesia. Otherwise in stable medical condition (ASA status 1 or 2).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10023696 Laparotomy LLT
    12.0 10023697 Laparotomy & drainage LLT
    12.0 10051777 Staging laparotomy LLT
    12.0 10053361 Explorative laparotomy LLT
    12.0 10023693 Laparoscopy LLT
    12.0 10069054 Pelvic laparoscopy LLT
    12.0 10006187 Breast cancer LLT
    12.0 10006188 Breast cancer female NOS LLT
    12.0 10006193 Breast cancer NOS recurrent LLT
    12.0 10006198 Breast cancer recurrent LLT
    12.0 10006203 Breast cancer stage unspecified LLT
    12.0 10021944 Infiltrating ductal breast cancer LLT
    12.0 10021974 Inflammatory breast cancer LLT
    12.0 10022779 Intraductal breast cancer (in situ) LLT
    12.0 10025025 Lumpectomy (breast cancer) LLT
    12.0 10027475 Metastatic breast cancer LLT
    12.0 10028058 Mucinous breast cancer LLT
    12.0 10048406 Breast cancer aggravated LLT
    12.0 10055113 Breast cancer metastatic LLT
    12.0 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005315-26 Sponsor Protocol Number: A25165 Start Date*: 2008-07-01
    Sponsor Name:CONRAD, Eastern Virgina Medical School
    Full Title: Sperm Suppression and Contraceptive Protection provived by Norethisterone Enantate (NET-EN) combined with Testosterone Undecanoate (TU) in healthy men.
    Medical condition: The proposed study is designed to evaluate whether the combination of a progestin, norethisterone enantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effective ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Temporarily Halted) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-000876-40 Sponsor Protocol Number: IJB-REGINA-2020 Start Date*: 2021-03-09
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN stage II-III rectAl cancer
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015884-15 Sponsor Protocol Number: IMPAACT-P1066 Start Date*: 2011-06-30
    Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD
    Full Title: A Phase I/II, Multicenter, Open-Label, Non comparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmac...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002588-23 Sponsor Protocol Number: 2019/0407/HP Start Date*: 2023-03-13
    Sponsor Name:CHU de Rouen
    Full Title: Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy: A randomized phase III trial - COnCERTO (French 01-18)
    Medical condition: Patients first treated by stoma and requiring chemotherapy for obstructive colon cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10042613 - Surgical and medical procedures 10073254 Neoadjuvant therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020077-16 Sponsor Protocol Number: B1801031 Start Date*: 2010-12-22
    Sponsor Name:Pfizer, S.A
    Full Title: Estudio de 12 semanas de duración, multicéntrico, doble ciego, controlado con placebo, aleatorizado de etanercept con un AINE de base en el tratamiento de sujetos adultos con espondiloartritis axia...
    Medical condition: Espondiloartritis axial (AxSpA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051265 Spondyloarthropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) DE (Completed) BE (Completed) GB (Completed) DK (Prematurely Ended) NL (Completed) FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004483-11 Sponsor Protocol Number: 80-83600-98-40120 Start Date*: 2016-07-08
    Sponsor Name:University Medical Center Utrecht
    Full Title: Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition
    Medical condition: schizophrenia, schizoaffective, schizophreniform disorder or psychosis not otherwhise specified (DSM-IV 295.*)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039635 Schizophrenia schizoaffective LLT
    21.1 100000004873 10039648 Schizophreniform illness LLT
    20.0 100000004873 10039632 Schizophrenia NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003326-41 Sponsor Protocol Number: 200719 Start Date*: 2016-01-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor
    Medical condition: Preterm Labour
    Disease: Version SOC Term Classification Code Term Level
    19.1 10036585 - Pregnancy, puerperium and perinatal conditions 10036600 Premature labour PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003408-65 Sponsor Protocol Number: Start Date*: 2016-08-26
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
    Medical condition: Heavy menstrual bleeding
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046784 Uterine fibroids LLT
    18.0 10038604 - Reproductive system and breast disorders 10027313 Menorrhagia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 02:11:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA